2
2
1
1
2
2
2
2
2
2
1
1
1
1
1
1
2
2
1
1
2017
2006
Company (23)University (5)
1 - 10 of 23
Sort by
Patent
Publication NumberEP 2219635 B1Filing StatusIssued PatentAvailabilityUnknownFiling Date2008-10-20Publication Date2017-01-25
Research Grant
IDW15QKN-16-C-0024Funding AgencyDepartment of DefenseEffective Date2016-08-11Expiration Date2017-08-10Funding Amount$499,916
Two small businesses have teamed towards a Phase II Enhancement based on their unique qualifications to meet the requirements of the Army. Omm Scientific, Inc. is currently working with their Air Force customer under a Phase II STTR effort focused on converting Diaminoazofurazan (DAAzF) to aminonitroazafurazan (ANAzF). Although ANAzF may be a useful propellant ingredient, it is not useful for explosive applications or of interest to the Army. Nalas Engineering Services, Inc. (also small busin…
Research Grant
Project Number5R41AI115897-02Funding AgencyNational Institutes of HealthEffective Date2016-02-01Expiration Date2017-09-30Funding Amount$110,265
? DESCRIPTION (provided by applicant): The long-term goal of this project is to gain FDA approval for commercialization of a broad- spectrum small-molecule antiviral agent that is effective in treating Ebola virus (EBOV) and Marburg virus (MARV). These pathogens are major biothreat agents for which there are no approved therapeutic options or vaccines. The developed drug will inhibit a conserved human cellular target whose activity is necessary for infection by these and many other prominent …
Research Grant
Project Number1R41AI115897-01Funding AgencyNational Institutes of HealthEffective Date2015-02-01Expiration Date2016-01-31Funding Amount$328,211
? DESCRIPTION (provided by applicant): The long-term goal of this project is to gain FDA approval for commercialization of a broad- spectrum small-molecule antiviral agent that is effective in treating Ebola virus (EBOV) and Marburg virus (MARV). These pathogens are major biothreat agents for which there are no approved therapeutic options or vaccines. The developed drug will inhibit a conserved human cellular target whose activity is necessary for infection by these and many other prominent …
Research Grant
IDN68936-14-C-0061Funding AgencyDepartment of DefenseEffective Date2014-05-22Expiration Date2014-11-21Funding Amount$79,996
The overall technical objective is to identify one or more promising synthetic methods for the preparation of a direct intermediate to CL-20 that uses commodity reagents and enable CL-20 to be prepared at a price of $150/lb. The intermediate will likely be a tetra- or hexa-acyl hexaazaisowurtzitane cage known to be convertible to CL-20 in good yield. The Phase I approach is to rapidly determine feasibility of five proposed routes to a direct CL-20 precursor. LC/MS analytical methods will be …
Research Grant
Project Number261201300020C-0-0-1Funding AgencyNational Institutes of HealthEffective Date2013-01-01Expiration Date2013-12-31Funding Amount$249,997
Radiation insensitive tumors that become radiation resistant are often also invasive, metastatic, and responsible for most cancer deaths. Here, the long term objective is to complete clinical evaluation of an inhibitor of a new target (V-ATPase) that sensitizes tumors but not healthy tissues to radiation and inhibits multiple aspects of tumor metabolism and therapeutic resistance. Development of the inhibitor begins with its preparation and determination of its lifetime in cell culture media …
Research Grant
IDFA9300-13-C-2501Funding AgencyDepartment of DefenseEffective Date2012-12-06Expiration Date2015-03-03Funding Amount$749,999
ABSTRACT: This proposal sets out a plan to continue the method development for selective chemical oxidization of one amine of a polyamino, multi-heterocyclic class of energetic materials. The approach is based on screening one substrate (DAAzF) with many different oxidants under a variety of conditions including microwave heating to find those conditions where one amine group has been oxidized to a nitro group to give ANAzF. The reaction mixtures are analyzed by liquid chromatography/mass …
Patent
Publication NumberUS 8252841Filing StatusIssued PatentAvailabilityUnknownFiling Date2008-10-20Publication Date2012-08-28
The present invention relates to compounds and methods for the treatment of bacterial infections. Because their mechanism of action does not involve killing of bacteria or inhibiting their growth, the potential for these compounds to induce drug resistance in bacteria is minimized. Through inhibiting bacterial virulence, the present invention provides a novel means of treating bacterial infections.
Research Grant
IDFA9300-11-M-6003Funding AgencyDepartment of DefenseEffective Date2011-09-30Funding Amount$100,000
ABSTRACT: New energetic materials are needed for use in explosives and propellants that have a very powerful energy release yet are insensitive to handling. Safer materials that also allow development of lighter weight, longer range missiles and higher performance explosives are needed. One class of such compounds is materials based on furazan heterocycles. While some furazans are too energetic, others have very attractive properties but are difficult or unsafe to make. To address this c…
Research Grant
Project Number261201100085C-0-0-1Funding AgencyNational Institutes of HealthEffective Date2011-01-01Expiration Date2011-12-31Funding Amount$199,931
Invasive, metastatic, and/or drug resistant cancers are responsible for most cancer deaths. Development of a drug that blocks these phenotypes to improve outcomes is the ultimate objective. The specific means is by inhibiting the acidification of extra-cellular and extra-tumoral environments that otherwise facilitates invasion, metastasis, and drug resistance. The lead, RD203, potently inhibits the V-ATPase pump largely responsible for acidification and shows compelling anticancer activities.…
We found 23 documents that match your Search
Research Grants: 10
Patents: 13

Wellspring Search is the world's most comprehensive collection of enriched content about emerging and licensable technology innovations.


Already a member? Sign in